Working together to change lives with targeted genetic therapies

Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies. Founded by scientists at Mayo Clinic, Vyriad has remained rooted in Rochester, Minnesota, where the company’s founding mission to realize the potential of engineered viruses has evolved into partnerships with leading medical institutions and pharmaceutical companies that are advancing the development of genetic therapies around the world.

Over the past decade, Vyriad has cultivated a deep expertise in engineering targeted, efficient and stable virus platforms to facilitate a variety of applications, including in vivo gene therapies, gene editing and oncolytic virotherapy. Our innovations have emerged from purposeful collaborations and a holistic approach to therapeutic development that combines capabilities in preclinical development, manufacturing, and clinical expertise.

In collaboration with Regeneron, Mayo Clinic and other research and medical institutions, we have successfully developed oncolytic virotherapies derived from either vesicular stomatitis virus (VSV) or measles virus therapies for the treatment of cancers, which are now in ongoing Phase 1-2 clinical trials addressing multiple cancer types. A strategic collaboration with Regeneron is ongoing to discover and develop new oncolytic virotherapies that leverage Vyriad’s VSV platform, as well as Regeneron’s unmatched antibody discovery capabilities.

Vyriad is privately held and based in Rochester, Minnesota. Its 12,000 square foot facility on the Rochester Technology Center campus includes offices, state of the art research laboratories, a GMP-certified manufacturing facility and support systems for multicenter oncolytic virotherapy clinical trials.